Business Context and Reporting Period
This Form 6-K filing by Zhengye Biotechnology Holding Limited covers the month of May 2025, specifically dated May 23, 2025. The filing serves to disclose the receipt of a NASDAQ Delinquency Notice regarding the company's failure to timely file its annual report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice and does not contain financial statements or performance data.
Material Changes
The primary material event is the receipt of a notice from NASDAQ Regulation on May 20, 2025. The company is not in compliance with NASDAQ Listing Rule 5250(c)(1) due to the failure to file its Form 20-F for the fiscal year ended December 31, 2024, by the May 15, 2025 deadline.
Guidance, Outlook, and Risks
- Risk: The company faces potential delisting risks associated with non-compliance with NASDAQ listing rules regarding timely filing of annual reports.
- Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the receipt of the notice but provides no further strategic outlook or management commentary within the text of the Form 6-K itself.
- Unusual Items: The delinquency notice is the sole unusual item reported in this filing.
Investor Verification Checklist
- Verify the current status of the Form 20-F for the fiscal year ended December 31, 2024, to determine if it has been filed subsequent to this notice.
- Review the full text of the attached press release (Exhibit 99.1) for any proposed remediation plans or timelines to regain compliance.
- Monitor NASDAQ communications for any further actions, such as a hearing request or delisting determination.
- Confirm whether the company has issued any other disclosures regarding its financial condition or operational status since the May 20, 2025 notice.